CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $45.4 million in its fourth quarter.
The Cambridge, Massachusetts-based company said it had a loss of 55 cents per share.
The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The genome editing company posted revenue of $30.6 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $37.9 million.
For the year, the company reported a loss of $237.1 million, or $2.88 per share. Revenue was reported as $32.3 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。